Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors

American Journal of Pathology

Volumn 156, Issue 5, 2000, Pages 1693-1700

  Gimm, Oliver ^a   Perren, Aurel ^a,b   Weng, Liang Ping ^a   Marsh, Debbie J ^a,c   Yeh, Jen Jen ^c   Ziebold, Ulrike ^d   Gil, Elad ^d   Hinze, Raoul ^e   Delbridge, Leigh ^f   Lees, Jacqueline A ^d   Mutter, George L ^g   Robinson, Bruce G ^f   Komminoth, Paul ^b   Dralle, Henning ^e   Eng, Charis ^a,h  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f UNIVERSITY OF SYDNEY   (Australia)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

ANIMAL CELL; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; COWDEN SYNDROME; CYTOPLASM; GENE EXPRESSION; GENE MUTATION; GERM LINE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID ADENOMA; THYROID CARCINOMA; THYROID FOLLICLE CELL; TUMOR SUPPRESSOR GENE;

EID: 0033843623     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65040-7     Document Type: Article

References (45)

1. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
2. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
3. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta
4. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines
5. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase
6. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate
7. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function
8. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
9. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC
10. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies
11. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN
12. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways
13. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells
14. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human gliobtastoma cells
15. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death
16. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
17. Germline mutations in PTEN are present in Bannayan-Zonana syndrome
18. Genetics of Cowden syndrome: Through the looking glass of oncology
19. Cowden's disease: A case report and review of the literature
20. Cowden's disease (multiple hamartoma syndrome)
21. Cowden's disease: Analysis of fourteen new cases
22. Pten is essential for embryonic development and tumour suppression
23. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems
24. Differential loss of heterozygosity in the region of the Cowden locus within 10q22-23 in follicular thyroid adenomas and carcinomas
25. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors
26. Fine structure deletion analysis of 10q22-24 demonstrates regions of loss and suggests that sporadic follicular adenomas and follicular thyroid adenomas develop along distinct parallel neoplastic pathways
27. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors
28. The WHO histological classification of thyroid tumors: A commentary on the ed 2
29. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast
30. Transcriptional analysis of the PTEN/MMAC1 pseudogene, psiPTEN
31. Antigen retrieval, signal amplification and intensification in immunohistochemistry
32. Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma
33. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer
34. Statistical aspects for the analysis from retrospective studies of disease
35. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene
36. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: Differential involvement of focal adhesion kinase and p130Cas
37. Inactivation of the tumor suppressor PTEN/MMAC 1 in advanced human prostate cancer through loss of expression
38. Functions of the MDM2 oncoprotein
39. A difficult Akt to follow
40. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor
41. Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent
42. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma
43. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas
44. Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas
45. Deletions of the long arm of chromosome 10 in progression of follicular thyroid tumors